Early pregnancy interruption with a single PGF2 alpha 15-methyl-analogue vaginal suppository.
Pregnancy was interrupted successfully in 70% of 20 early pregnancies, 35-49 days in duration as dated from the first day of the last menstrual period, by administration of a single intravaginal suppository containing 3 mg of (15S)-15-methyl prostaglandin F2 alpha (PGF2 alpha). No correlation could be demonstrated with baseline beta-subunit human chorionic gonadotropin or serum levels of prostaglandin obtained within ten hours of treatment. Continued pregnancy was documented in 10%. The rate of failures and the frequency of gastrointestinal side effects were deemed too great to warrant adopting this agent for clinical usage.
D000028:Abortion, Induced / Q000009:adverse effects; D000328:Adult; D003430:Cross-Sectional Studies; D015237:Dinoprost / Q000031:analogs & derivatives*; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D012494:Sampling Studies; D013488:Suppositories; D013997:Time Factors; D014621:Vagina
D011461:Prostaglandins F, Synthetic; D013488:Suppositories; D011374:Progesterone; C030319:prostaglandin F2alpha 15-methyl ether; D015237:Dinoprost